Posted on 2/24/19
Kraft Heinz: Writedown And SEC Probe Are Actually Worse Than They Look
Kraft Heinz (KHC) has left investors shocked after reporting a big loss in Q4 2018, fueled by a staggering $15.4 billion writedown to a number of . . .
Posted on 2/24/19
Kraft Heinz: Writedown And SEC Probe Are Actually Worse Than They Look
Kraft Heinz (KHC) has left investors shocked after reporting a big loss in Q4 2018, fueled by a staggering $15.4 billion writedown to a number of . . .
Posted on 7/31/18
Progenics Wins Big With Azedra Approval
SummaryOn July 30th, the FDA gave the green-light to Azedra, the company’s radiotherapy product designed to treat a pair of rare and lethal adrenal gland cancers.Azedra . . .
Posted on 5/24/18
Novavax: All Eyes On Q1 2019
Novavax (NVAX) has experienced many ups and downs in recent years. This has largely been the product of exuberance about its adult RSV vaccine trial, which . . .
Posted on 1/19/18
Berkshire Without Buffett: Will It Flounder Without The Oracle At The Helm?
That old adage came to mind last week when I read of the latest internal moves at Berkshire Hathaway (BRK.A) (BRK.B). The company announced on January . . .
Posted on 10/17/17
Novavax: Down A CFO But Not Out
With a share price still severely depressed after the failure of its older adult RSV vaccine trial in September 2016, Novavax (NVAX) has yet to bounce . . .
Posted on 9/14/17
Novavax: Catalysts Building Toward A Crescendo
Novavax (NVAX) has had a long and bumpy road. Suffering badly after its key trial of an adult RSV vaccine went bust in 2016, the stock . . .
Posted on 8/23/17
Novavax: The Case For Going Long
Novavax (NASDAQ: NVAX) is a clinical-stage biotech company with an enviable pipeline, including a vaccine for respiratory syncytial virus (RSV), a disease that afflicts millions of . . .
Philadelphia
